{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:06:19Z","timestamp":1788264379198,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>In this study, based on PET\/CT radiomics features, we developed and validated a nomogram to predict progression-free survival (PFS) for cases with diffuse large B cell lymphoma (DLBCL) treated with immunochemotherapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study retrospectively recruited 129 cases with DLBCL. Among them, PET\/CT scans were conducted and baseline images were collected for radiomics features along with their clinicopathological features. Radiomics features related to recurrence were screened for survival analysis using univariate Cox regression analysis with<jats:italic>p<\/jats:italic>&lt; 0.05. Next, a weighted Radiomics-score (Rad-score) was generated and independent risk factors were obtained from univariate and multivariate Cox regressions to build the nomogram. Furthermore, the nomogram was tested for their ability to predict PFS using time-dependent receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Blood platelet, Rad-score, and gender were included in the nomogram as independent DLBCL risk factors for PFS. We found that the training cohort areas under the curve (AUCs) were 0.79, 0.84, and 0.88, and validation cohort AUCs were 0.67, 0.83, and 0.72, respectively. Further, the DCA and calibration curves confirmed the predictive nomogram\u2019s clinical relevance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Using Rad-score, blood platelet, and gender of the DLBCL patients, a PET\/CT radiomics-based nomogram was developed to guide cases\u2019 recurrence risk assessment prior to treatment. The developed nomogram can help provide more appropriate treatment plans to the cases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key Points<\/jats:title><jats:p><jats:italic>\u2022 DLBCL cases can be classified into low- and high-risk groups using PET\/CT radiomics based Rad-score.<\/jats:italic><\/jats:p><jats:p><jats:italic>\u2022 When combined with other clinical characteristics (gender and blood platelet count), Rad-score can be used to predict the outcome of the pretreatment of DLBCL cases with a certain degree of accuracy.<\/jats:italic><\/jats:p><jats:p><jats:italic>\u2022 A prognostic nomogram was established in this study in order to aid in assessing prognostic risk and providing more accurate treatment plans for DLBCL cases.<\/jats:italic><\/jats:p><\/jats:sec>","DOI":"10.1007\/s00330-022-09301-5","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T15:03:16Z","timestamp":1671721396000},"page":"3354-3365","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Development and validation of a [18F]FDG PET\/CT-based radiomics nomogram to predict the prognostic risk of pretreatment diffuse large B cell lymphoma patients"],"prefix":"10.1007","volume":"33","author":[{"given":"Mingshan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-5812","authenticated-orcid":false,"given":"Kezheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,22]]},"reference":[{"key":"9301_CR1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","volume":"50","author":"S Li","year":"2018","unstructured":"Li S, Young K, Medeiros L (2018) Diffuse large B-cell lymphoma. Pathology 50:74\u201387","journal-title":"Pathology"},{"issue":"551-568","key":"9301_CR2","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD et al (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37(551-568):e514","journal-title":"Cancer Cell"},{"key":"9301_CR3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.2019002729","volume":"135","author":"A Ruppert","year":"2020","unstructured":"Ruppert A, Dixon J, Salles G et al (2020) International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 135:2041\u20132048","journal-title":"Blood"},{"key":"9301_CR4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nrclinonc.2017.78","volume":"14","author":"J Cunningham","year":"2017","unstructured":"Cunningham J, Iyengar S, Sharma B (2017) Evolution of lymphoma staging and response evaluation: current limitations and future directions. Nat Rev Clin Oncol 14:631\u2013645","journal-title":"Nat Rev Clin Oncol"},{"key":"9301_CR5","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1200\/JCO.2014.57.7080","volume":"33","author":"K Dybk\u00e6r","year":"2015","unstructured":"Dybk\u00e6r K, B\u00f8gsted M, Falgreen S et al (2015) Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis. J Clin Oncol 33:1379\u20131388","journal-title":"J Clin Oncol"},{"key":"9301_CR6","doi-asserted-by":"crossref","first-page":"768098","DOI":"10.3389\/fimmu.2021.768098","volume":"12","author":"W Liu","year":"2021","unstructured":"Liu W, Deng Y, Li Z et al (2021) Cancer Evo-Dev: a theory of inflammation-induced oncogenesis. Front Immunol 12:768098","journal-title":"Front Immunol"},{"key":"9301_CR7","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s12149-018-1299-z","volume":"33","author":"J Xu","year":"2019","unstructured":"Xu J, Li Y, Hu S, Lu L, Gao Z, Yuan H (2019) The significant value of predicting prognosis in patients with colorectal cancer using (18)F-FDG PET metabolic parameters of primary tumors and hematological parameters. Ann Nucl Med 33:32\u201338","journal-title":"Ann Nucl Med"},{"key":"9301_CR8","doi-asserted-by":"crossref","first-page":"e606","DOI":"10.1016\/j.clml.2020.03.007","volume":"20","author":"A Mohsen","year":"2020","unstructured":"Mohsen A, Taalab M, Abousamra N, Mabed M (2020) Prognostic significance of absolute lymphocyte count, absolute monocyte count, and absolute lymphocyte count to absolute monocyte count ratio in follicular non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 20:e606\u2013e615","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"9301_CR9","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3389\/fonc.2019.01392","volume":"9","author":"J Yang","year":"2019","unstructured":"Yang J, Guo X, Hao J, Dong Y, Zhang T, Ma X (2019) The prognostic value of blood-based biomarkers in patients with testicular diffuse large B-cell lymphoma. Front Oncol 9:1392","journal-title":"Front Oncol"},{"key":"9301_CR10","doi-asserted-by":"crossref","unstructured":"Voltin CA, Mettler J, Grosse J et al (2020) FDG-PET imaging for Hodgkin and diffuse large B-cell lymphoma-an updated overview. Cancers (Basel) 12(3):601","DOI":"10.3390\/cancers12030601"},{"key":"9301_CR11","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1007\/s00259-019-04363-y","volume":"46","author":"S Chen","year":"2019","unstructured":"Chen S, He K, Feng F et al (2019) Metabolic tumor burden on baseline (18)F-FDG PET\/CT improves risk stratification in pediatric patients with mature B-cell lymphoma. Eur J Nucl Med Mol Imaging 46:1830\u20131839","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9301_CR12","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00259-019-04309-4","volume":"46","author":"QA Shagera","year":"2019","unstructured":"Shagera QA, Cheon GJ, Koh Y et al (2019) Prognostic value of metabolic tumour volume on baseline (18)F-FDG PET\/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. Eur J Nucl Med Mol Imaging 46:1417\u20131427","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9301_CR13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","volume":"14","author":"P Lambin","year":"2017","unstructured":"Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol 14:749\u2013762","journal-title":"Nat Rev Clin Oncol"},{"key":"9301_CR14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejca.2011.11.036","volume":"48","author":"P Lambin","year":"2012","unstructured":"Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441\u2013446","journal-title":"Eur J Cancer"},{"key":"9301_CR15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3322\/caac.21552","volume":"69","author":"WL Bi","year":"2019","unstructured":"Bi WL, Hosny A, Schabath MB et al (2019) Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J Clin 69:127\u2013157","journal-title":"CA Cancer J Clin"},{"key":"9301_CR16","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1097\/RLU.0000000000002732","volume":"44","author":"KH Lue","year":"2019","unstructured":"Lue KH, Wu YF, Liu SH et al (2019) Prognostic value of pretreatment radiomic features of 18F-FDG PET in patients with Hodgkin lymphoma. Clin Nucl Med 44:e559\u2013e565","journal-title":"Clin Nucl Med"},{"key":"9301_CR17","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1007\/s00330-020-06815-8","volume":"30","author":"N Aide","year":"2020","unstructured":"Aide N, Fruchart C, Nganoa C, Gac AC, Lasnon C (2020) Baseline (18)F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. Eur Radiol 30:4623\u20134632","journal-title":"Eur Radiol"},{"key":"9301_CR18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00259-017-3899-6","volume":"45","author":"N Aide","year":"2018","unstructured":"Aide N, Talbot M, Fruchart C, Damaj G, Lasnon C (2018) Diagnostic and prognostic value of baseline FDG PET\/CT skeletal textural features in diffuse large B cell lymphoma. Eur J Nucl Med Mol Imaging 45:699\u2013711","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9301_CR19","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00259-009-1297-4","volume":"37","author":"R Boellaard","year":"2010","unstructured":"Boellaard R, O'Doherty MJ, Weber WA et al (2010) FDG PET and PET\/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181\u2013200","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9301_CR20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"9301_CR21","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer MJ, Ghesquieres H, Jais JP et al (2014) Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol 32:1066\u20131073","journal-title":"J Clin Oncol"},{"key":"9301_CR22","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2018.77.9124","volume":"36","author":"Q Shi","year":"2018","unstructured":"Shi Q, Schmitz N, Ou FS et al (2018) Progression-free survival as a surrogate end point for overall survival in first-line diffuse large B-cell lymphoma: an individual patient-level analysis of multiple randomized trials (SEAL). J Clin Oncol 36:2593\u20132602","journal-title":"J Clin Oncol"},{"key":"9301_CR23","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2967\/jnumed.114.149625","volume":"56","author":"MJ Wondergem","year":"2015","unstructured":"Wondergem MJ, Rizvi SN, Jauw Y et al (2015) 18F-FDG or 3'-deoxy-3'-18F-fluorothymidine to detect transformation of follicular lymphoma. J Nucl Med 56:216\u2013221","journal-title":"J Nucl Med"},{"key":"9301_CR24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/MNM.0b013e328342b9d2","volume":"32","author":"M Karam","year":"2011","unstructured":"Karam M, Feustel PJ, Vera CD, Nazeer T (2011) Features of large cell transformation of indolent lymphomas as observed on sequential PET\/CT. Nucl Med Commun 32:177\u2013185","journal-title":"Nucl Med Commun"},{"key":"9301_CR25","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood.2019001091","volume":"135","author":"F Mir","year":"2020","unstructured":"Mir F, Barrington SF, Brown H et al (2020) Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study. Blood 135:1214\u20131218","journal-title":"Blood"},{"key":"9301_CR26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.semnuclmed.2017.09.005","volume":"48","author":"L Kostakoglu","year":"2018","unstructured":"Kostakoglu L, Chauvie S (2018) Metabolic tumor volume metrics in lymphoma. Semin Nucl Med 48:50\u201366","journal-title":"Semin Nucl Med"},{"key":"9301_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00259-018-4173-2","volume":"46","author":"D Albano","year":"2019","unstructured":"Albano D, Bosio G, Pagani C et al (2019) Prognostic role of baseline 18F-FDG PET\/CT metabolic parameters in Burkitt lymphoma. Eur J Nucl Med Mol Imaging 46:87\u201396","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9301_CR28","doi-asserted-by":"crossref","first-page":"14593","DOI":"10.18632\/aging.103508","volume":"12","author":"Z Liu","year":"2020","unstructured":"Liu Z, Cao Y, Diao W, Cheng Y, Jia Z, Peng X (2020) Radiomics-based prediction of survival in patients with head and neck squamous cell carcinoma based on pre- and post-treatment F-PET\/CT. Aging 12:14593\u201314619","journal-title":"Aging"},{"key":"9301_CR29","doi-asserted-by":"crossref","first-page":"613918","DOI":"10.3389\/fmolb.2020.613918","volume":"7","author":"D Cai","year":"2020","unstructured":"Cai D, Duan X, Wang W et al (2020) A metabolism-related radiomics signature for predicting the prognosis of colorectal cancer. Front Mol Biosci 7:613918","journal-title":"Front Mol Biosci"},{"key":"9301_CR30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12885-020-6520-5","volume":"20","author":"B Gu","year":"2020","unstructured":"Gu B, Zhang J, Ma G et al (2020) Establishment and validation of a nomogram with intratumoral heterogeneity derived from F-FDG PET\/CT for predicting individual conditional risk of 5-year recurrence before initial treatment of nasopharyngeal carcinoma. BMC cancer 20:37","journal-title":"BMC cancer"},{"key":"9301_CR31","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s00330-018-5861-9","volume":"29","author":"W Li","year":"2019","unstructured":"Li W, Zhang L, Tian C et al (2019) Prognostic value of computed tomography radiomics features in patients with gastric cancer following curative resection. Eur Radiol 29:3079\u20133089","journal-title":"Eur Radiol"},{"key":"9301_CR32","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1007\/s00259-019-04420-6","volume":"46","author":"ME Mayerhoefer","year":"2019","unstructured":"Mayerhoefer ME, Riedl CC, Kumar A et al (2019) Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma. Eur J Nucl Med Mol Imaging 46:2760\u20132769","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9301_CR33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","volume":"61","author":"AS Cottereau","year":"2020","unstructured":"Cottereau AS, Nioche C, Dirand AS et al (2020) (18)F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J Nucl Med 61:40\u201345","journal-title":"J Nucl Med"},{"key":"9301_CR34","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1126\/science.1256930","volume":"346","author":"J Zhang","year":"2014","unstructured":"Zhang J, Fujimoto J, Zhang J et al (2014) Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346:256\u2013259","journal-title":"Science"},{"key":"9301_CR35","first-page":"147","volume":"4","author":"CK Meikle","year":"2016","unstructured":"Meikle CK, Kelly CA, Garg P, Wuescher LM, Ali RA, Worth RG (2016) Cancer and thrombosis: the platelet perspective. Front Cell Dev Biol 4:147","journal-title":"Front Cell Dev Biol"},{"key":"9301_CR36","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1002\/ijc.27441","volume":"130","author":"D Buergy","year":"2012","unstructured":"Buergy D, Wenz F, Groden C, Brockmann MA (2012) Tumor-platelet interaction in solid tumors. Int J Cancer 130:2747\u20132760","journal-title":"Int J Cancer"},{"key":"9301_CR37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1477-7819-12-37","volume":"12","author":"M Kim","year":"2014","unstructured":"Kim M, Chang H, Yang HC et al (2014) Preoperative thrombocytosis is a significant unfavorable prognostic factor for patients with resectable non-small cell lung cancer. World J Surg Oncol 12:37","journal-title":"World J Surg Oncol"},{"key":"9301_CR38","doi-asserted-by":"crossref","first-page":"971","DOI":"10.3109\/0284186X.2014.1000466","volume":"54","author":"AS Chadha","year":"2015","unstructured":"Chadha AS, Kocak-Uzel E, Das P et al (2015) Paraneoplastic thrombocytosis independently predicts poor prognosis in patients with locally advanced pancreatic cancer. Acta Oncol 54:971\u2013978","journal-title":"Acta Oncol"},{"key":"9301_CR39","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/s41598-017-01652-0","volume":"7","author":"C Pedrazzani","year":"2017","unstructured":"Pedrazzani C, Mantovani G, Fernandes E et al (2017) Assessment of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and platelet count as predictors of long-term outcome after R0 resection for colorectal cancer. Sci Rep 7:1494","journal-title":"Sci Rep"},{"key":"9301_CR40","first-page":"9651254","volume":"2018","author":"S Wang","year":"2018","unstructured":"Wang S, Ma Y, Sun L et al (2018) Prognostic significance of pretreatment neutrophil\/lymphocyte ratio and platelet\/lymphocyte ratio in patients with diffuse large B-cell lymphoma. Biomed Res Int 2018:9651254","journal-title":"Biomed Res Int"},{"key":"9301_CR41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay LJ, Felding-Habermann B (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11:123\u2013134","journal-title":"Nat Rev Cancer"},{"key":"9301_CR42","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1182\/blood-2017-05-743187","volume":"131","author":"XR Xu","year":"2018","unstructured":"Xu XR, Yousef GM, Ni H (2018) Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood 131:1777\u20131789","journal-title":"Blood"},{"key":"9301_CR43","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1002\/lary.27074","volume":"128","author":"SA Hong","year":"2018","unstructured":"Hong SA, Tajudeen BA, Choi S, Husain IA (2018) Epidemiology and prognostic indicators in laryngeal lymphoma: a population-based analysis. Laryngoscope 128:2044\u20132049","journal-title":"Laryngoscope"},{"key":"9301_CR44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008135","volume":"4","author":"J Prescott","year":"2009","unstructured":"Prescott J, Lu Y, Chang ET et al (2009) Reproductive factors and non-Hodgkin lymphoma risk in the California Teachers Study. PLoS One 4:e8135","journal-title":"PLoS One"},{"key":"9301_CR45","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-020-00382-3","volume":"10","author":"JE Krull","year":"2020","unstructured":"Krull JE, Wenzl K, Hartert KT et al (2020) Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH\/TH DLBCL patients. Blood Cancer J 10:117","journal-title":"Blood Cancer J"},{"key":"9301_CR46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.blre.2016.09.004","volume":"31","author":"A Rosenthal","year":"2017","unstructured":"Rosenthal A, Younes A (2017) High grade B-cell lymphoma with rearrangements of MYC and BCL2 and\/or BCL6: double hit and triple hit lymphomas and double expressing lymphoma. Blood Rev 31:37\u201342","journal-title":"Blood Rev"},{"key":"9301_CR47","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","volume":"21","author":"G Salles","year":"2020","unstructured":"Salles G, Duell J, Gonz\u00e1lez Barca E et al (2020) Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. Lancet Oncol 21:978\u2013988","journal-title":"Lancet Oncol"},{"key":"9301_CR48","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1038\/s41375-020-0743-y","volume":"34","author":"G Lenz","year":"2020","unstructured":"Lenz G, Hawkes E, Verhoef G et al (2020) Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia 34:2184\u20132197","journal-title":"Leukemia"},{"key":"9301_CR49","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2017-08-802561","volume":"131","author":"CS Sauter","year":"2018","unstructured":"Sauter CS, Matasar MJ, Schoder H et al (2018) A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL. Blood 131:1805\u20131808","journal-title":"Blood"},{"key":"9301_CR50","doi-asserted-by":"crossref","unstructured":"Ernst M, Oeser A, Besiroglu B et al (2021) Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev 9:Cd013365","DOI":"10.1002\/14651858.CD013365.pub2"},{"key":"9301_CR51","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","volume":"22","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Ai W, Alderuccio JP et al (2021) Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 22:790\u2013800","journal-title":"Lancet Oncol"},{"key":"9301_CR52","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jacr.2015.04.019","volume":"12","author":"MA Mazurowski","year":"2015","unstructured":"Mazurowski MA (2015) Radiogenomics: what it is and why it is important. J Am Coll Radiol 12:862\u2013866","journal-title":"J Am Coll Radiol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-09301-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-022-09301-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-022-09301-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,3]],"date-time":"2023-12-03T12:11:02Z","timestamp":1701605462000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-022-09301-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,22]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["9301"],"URL":"https:\/\/doi.org\/10.1007\/s00330-022-09301-5","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,22]]},"assertion":[{"value":"13 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Kezheng Wang.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"One of the authors (Mingshan Li) has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required for this study because the data were collected retrospectively.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 retrospective\u2022 prognostic study\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}